From: Prognostic models for complete recovery in ischemic stroke: a systematic review and meta-analysis
No. of model | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | Total (%) | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Predictors included | |||||||||||||||||||||||||
NIHSS score | Â | * | * | Â | * | * | * | Â | * | * | Â | * | * | * | * | * | * | * | Â | Â | * | * | * | 17 | (70.8) |
Age | Â | * | * | Â | * | * | Â | Â | Â | Â | Â | Â | * | * | * | * | * | * | * | * | * | * | * | 15 | (62.5) |
Infarct volume | * | Â | * | * | Â | * | Â | * | * | Â | * | * | Â | Â | Â | Â | Â | Â | Â | * | Â | Â | Â | 12 | (50.0) |
Infarct volume < 29.5 mL |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | * |  |  | ||
Infarct volume < 31.2 mL |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | * |  | ||
Infarct volume < 25.5 mL |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | * | ||
History of diabetes mellitus | Â | * | * | Â | * | * | Â | Â | Â | Â | Â | Â | * | * | * | * | * | Â | Â | Â | Â | Â | Â | 9 | (37.5) |
History of stroke | Â | * | * | Â | * | * | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | * | Â | Â | Â | * | * | * | 8 | (33.3) |
Prestroke disability | Â | * | * | Â | * | * | Â | Â | Â | Â | Â | Â | * | * | * | * | Â | Â | Â | Â | Â | Â | Â | 8 | (33.3) |
Small-vessel stroke | Â | * | * | Â | * | * | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | 4 | (16.7) |
Tissue-type plasminogen activator (t-PA use) | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | * | * | * | * | Â | Â | Â | Â | Â | Â | Â | 4 | (16.7) |
Preadmission modified Rankin scale | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | * | Â | Â | Â | * | * | * | 4 | (16.7) |
Sex | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | * | Â | Â | Â | * | * | * | 4 | (16.7) |
Atrial fibrillation | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | * | * | * | 3 | (12.5) |
Congestive heart failure | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | * | * | * | 3 | (12.5) |
Antiplatelet use | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | * | * | * | 3 | (12.5) |
Diffusion-weighted imaging lesion volume (DWI) | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | * | Â | * | Â | Â | Â | Â | Â | Â | Â | 2 | (8.3) |
Time to DWI scan | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | * | Â | * | Â | Â | Â | Â | Â | Â | Â | 2 | (8.3) |
Time by DWI interaction | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | * | Â | * | Â | Â | Â | Â | Â | Â | Â | 2 | (8.3) |
Barthel index | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | * | * | Â | Â | Â | 2 | (8.3) |
Neurological complications | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | * | Â | Â | Â | Â | Â | Â | 1 | (4.2) |
Fever > 38 °C |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | * |  |  |  |  |  |  | 1 | (4.2) |
Lenticulostriate arteries infarction | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | * | Â | Â | Â | Â | Â | Â | 1 | (4.2) |
Right arm weakness | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | * | Â | Â | Â | Â | Â | Â | 1 | (4.2) |
Left arm weakness | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | * | Â | Â | Â | Â | Â | Â | 1 | (4.2) |
Days to poststroke MRI scan | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | * | Â | Â | Â | 1 | (4.2) |
Hemisphere (left/right) | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | * | Â | Â | Â | 1 | (4.2) |
Total | 1 | 6 | 7 | 1 | 6 | 7 | 1 | 1 | 2 | 1 | 1 | 2 | 5 | 8 | 5 | 8 | 11 | 2 | 2 | 5 | 9 | 9 | 9 | Â | Â |